Addex Therapeutics Invests CHF 2 Million in Stalicla for CNS Innovation
Addex Drives Investment in Stalicla for Neuropsychiatric Solutions
Geneva-based Addex Therapeutics (SIX: ADXN) has taken a significant step in advancing treatment for neuropsychiatric disorders by leading a CHF 2 million investment in Stalicla. This clinical-stage company is dedicated to precision medicine aimed at addressing neurodevelopmental challenges. Stalicla plans to utilize these funds to enhance its portfolio of autism-focused drug candidates, facilitate partnerships for its key assets, and support its series C financing initiatives.
Strengthening Collaboration for Patient-Centric Care
As part of this strategic investment, Tim Dyer, CEO of Addex, will join the Board of Directors at Stalicla, also taking on the role of Chairman. Dyer expresses optimism about contributing to Stalicla’s mission: "This investment epitomizes our commitment to innovative CNS treatments and enhances our equity in Neurosterix. With Stalicla's advanced precision medicine platform, we aim to transform the treatment landscape for individuals on the autism spectrum. Our collaboration will be key in launching therapies that could genuinely change lives."
Advancing Clinical Trials for Autism Spectrum Disorders
The partnership allows both companies to leverage their strengths in developing effective therapies. Stalicla is preparing for Phase 2 trials for its leading candidate, STP1, which targets specific autism spectrum disorder (ASD) subpopulations. Moreover, the STP7 program (mavoglurant), which is currently the most advanced treatment for cocaine use disorder, is also set to progress through a Collaborative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA) of the NIH.
The Future of Autism Treatment
Stalicla's commitment to advancing treatments for autistic patients is further underscored by its CEO, Lynn Durham, who welcomes the onboarding of Addex. "Bringing in Addex and their investors represents a significant opportunity for us to enhance value for our shareholders. We are optimistic about initiating Phase 2 trials for our autism-focused drugs and believe this partnership will tremendously aid our mission."
About Stalicla: Pioneering Neurodevelopmental Disorder Treatments
Stalicla, a Swiss biopharmaceutical innovator, has successfully raised over $50 million in equity funding and more than $30 million in non-dilutive funding dedicated to transforming neurodevelopmental disorder treatment strategies. Their validated neuro precision development platform identifies stratified patient subgroups, enabling personalized treatment pathways that improve patient outcomes. Currently, Stalicla is gearing up to commence Phase 2 trials for its leading asset STP1 and another candidate, both specifically designed to address unique subpopulations within autism.
About Addex Therapeutics: Innovations in Neurology
Addex Therapeutics is at the forefront of developing unique small molecule allosteric modulators to treat neurological conditions. Their promising lead drug, dipraglurant, serves as an mGlu5 negative allosteric modulator (NAM) and is being evaluated for potential development in recovery from brain injuries such as strokes. In addition, their collaboration with Indivior focuses on advancing a GABAB PAM drug candidate for substance use disorders. Addex is also expanding its independent GABAB PAM program that targets chronic cough conditions.
Strategic Interests and Future Directions
Furthermore, Addex holds a 20% stake in Neurosterix LLC, which is advancing several allosteric modulator programs. Their current research includes promising candidates for schizophrenia, mood disorders, and neurocognitive issues. The shares of Addex Therapeutics are actively traded on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN," reflecting a solid commitment to advancing neurological health through innovation.
Frequently Asked Questions
What is the primary focus of Addex Therapeutics?
Addex Therapeutics primarily focuses on developing novel small molecule allosteric modulators aimed at treating neurological disorders.
How much has Addex invested in Stalicla?
Addex has led a significant investment of CHF 2 million in Stalicla to support their clinical endeavors in precision medicine.
What is Stalicla's mission?
Stalicla aims to transform the treatment landscape for neurodevelopmental disorders by focusing on precision medicine and personalized treatment options.
What conditions is Stalicla targeting with its clinical trials?
Stalicla is currently preparing for Phase 2 trials targeting autism spectrum disorders and cocaine use disorders.
Where can I find more information about Addex Therapeutics?
More information about Addex can be found on their official website: www.addextherapeutics.com.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
